Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 3/20 | 0.41 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10184454 | 0.93 | DGAT1 (0.44) | UTS2RDGAT1CHRNA7ACSL1EPHX2 | |
| SCHEMBL10186237 | 0.90 | FAAH (0.47) | DGAT1CLK1EPHX2FAAHMMP12 | |
| SCHEMBL10185623 | 0.89 | DGAT1 (0.51) | UTS2RDGAT1CHRNA7HTR3ACLK1 | |
| SCHEMBL10185239 | 0.87 | UTS2R (0.44) | UTS2RDGAT1CHRNA7HTR3ACLK1 | |
| SCHEMBL10185328 | 0.87 | CLK1 (0.56) | UTS2RDGAT1CHRNA7HTR3ACLK1 | |
| SCHEMBL10186473 | 0.87 | CLK1 (0.45) | UTS2RDGAT1CHRNA7HTR3ACLK1 | |
| SCHEMBL10186464 | 0.86 | DGAT1 (0.43) | DGAT1CHRNA7HTR3ACLK1HDAC1 | |
| SCHEMBL10185195 | 0.86 | DGAT1 (0.50) | DGAT1CLK1HDAC1 | |
| SCHEMBL10186138 | 0.84 | EPHX2 (0.53) | DGAT1EPHX2FAAHTEAD1 | |
| SCHEMBL10185348 | 0.84 | DGAT1 (0.49) | UTS2RDGAT1CHRNA7HTR3AMMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | UTS2R 2678/4885DGAT1 1/4885CHRNA7 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.